PHARMACEUTICAL CARE IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PHARMACO-ECONOMICAL BURDEN ON DIABETES PATIENT, COVID RECOVERED DIABETIC PATIENTS WITH CO-MORBID CONDITION.
Main Article Content
Keywords
Diabetes, COVID recovered diabetic patients, Pharmaceutical care, Pharmacoeconomic, Quality of life
Abstract
The worldwide commonness of diabetes is supposed to reach 10.5% (536.6 million individuals) by 2021, proposing a clinical emergency. Overseeing individuals with diabetes with comorbidities and those without COVID-19 overburdens the personal satisfaction and economy. To address this, medical care experts with clinical mastery have been attempting to foster a more extensive job in the therapy of diabetes. In spite of the fact that there is proof that drug treatment further develops glucose control, little is had some significant awareness of its impacts on human results, for example, wellbeing related personal satisfaction (HRQoL). The ebb and flow study incorporates a writing search in data sets, for example, IDF, CINAHL, Medline, Embase, Pubmed and worldwide articles by September 2021, alongside the extent of diabetes pharmacological treatment. For diabetics. Until this point in time, a couple of distributions have been distributed that show the pharmacological advantage of pharmacotherapy. There is no information to help guarantees that PCs have any sure monetary effect. This article surveys distributed examinations on the monetary investigation of medication organization to increment drug worth and supports the case that drug organization assists a PC with diminishing the monetary weight of patient downfall. locally by decreasing medication related dreariness and mortality.
References
1. Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients withtype 2 diabetes: Integration of the community pharmacist into the diabetes team - A pilot study. Pharm World Sci. 2004;26(1):18-25. doi:10.1023/B:PHAR.0000013465.24857.a8
2. Davis TME, Clifford RM, Davis WA, Batty KT. The role of pharmaceutical care in diabetes management. Br J Diabetes Vasc Dis. 2005;5(6):352-356. doi:10.1177/14746514050050061001
3. Borges APDS, Guidoni CM, Ferreira LD, Freitas O De, Pereira LRL. The pharmaceuticalcare of patients with type 2 diabetes mellitus. Pharm World Sci. 2010;32(6):730-736. doi:10.1007/s11096- 010-9428-3
4. Helper CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. American Journal of Hospital Pharmacists.1990; 47:533–43.
5. American Society of Hospital Pharmacists. ASHP statement on pharmaceutical care. American Journal of Hospital Pharmacy.1993; 50:1720–30.
6. De Sá Borges AP, Guidoni CM, de Freitas O, Pereira LRL. Avaliação econômica de pacientes ambulatoriais portadores de diabetes melito tipo 2 assistidos por um serviço de atenção farmacêutica. Arq Bras Endocrinol Metabol. 2011;55(9):686-691. doi:10.1590/S0004-27302011000900003
7. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: Updating the cost-of-illness model. J Am Pharm Assoc (Washington, DC 1996). 2001;41(2):192-199. doi:10.1016/S1086-5802(16)31229- 3
8. Jameson JP, Baty PJ. Pharmacist Collaborative Management of poorly controlled diabetesmellitus: A randomized controlled trial. Am J Manag Care. 2010;16(4):250-255. AccessedSeptember 26, 2021. https://www.ajmc.com/view/ajmc_10apr_jameson_250to255
9. Krass I, Armour CL, Mitchell B, et al. The pharmacy diabetes care program: Assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24(6):677-683. doi:10.1111/j.1464-5491.2007.02143.x
10. Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of a community pharmacist intervention in diabetes care: A randomized controlled trial. J Clin Pharm Ther. 2011;36(5):602-613. doi:10.1111/j.1365-2710.2010.01218.x
11. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist- managed diabetes care services in a community health center. Am J Heal Pharm. 2006;63(21):2116-2122. doi:10.2146/ajhp060040
12. Royal S, Smeaton L, Avery AJ, Hurwitz B, Sheikh A. Interventions in primary care to reduce medication related adverse events and hospital admissions: Systematic review andmeta-analysis. Qual Saf Heal Care. 2006;15(1):23-31. doi:10.1136/qshc.2004.012153
13. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med. 2008;358(6):580-591. doi:10.1056/nejmoa0706245
14. Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J.1998;317(7160):703-713. doi:10.1136/bmj.317.7160.703
15. Kinge JM, Sælensminde K, Dieleman J, Vollset SE, Norheim OF. Economic losses and burden of disease by medical conditions in Norway. Health Policy (New York). 2017;121(6):691-698. doi:10.1016/j.healthpol.2017.03.020
16. Cohen LB, Taveira TH, Khatana SAM, Dooley AG, Pirraglia PA, Wu WC. Pharmacist- Led Shared Medical Appointments for Multiple Cardiovascular Risk Reduction in PatientsWith Type 2 Diabetes. Diabetes Educ. 2011;37(6):801-812.doi:10.1177/0145721711423980
17. Armour CL, Taylor SJ, Hourihan F, Smith C, Krass I. Implementation and evaluation of Australian pharmacists’ diabetes care services. J Am Pharm Assoc. 2004;44(4):455-466. doi:10.1331/1544345041475625
18. Hae MC, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive casemanagement of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: Arandomized controlled trial. Am J Manag Care. 2005;11(4):253-260. Accessed September 26, 2021. https://www.ajmc.com/view/apr05-2017p0253-0260
19. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care programin a free medical clinic. Am J Med Qual. 2000;15(4):137-142. doi:10.1177/106286060001500403
20. Kumar CR. Basic Pathology, Prism PVT. Limited Bangalore, 5th edition, 1992, 569-587.
2. Ross and Wilson. Anatomy and Pathophysiology in Health and Illness, Churchill Livingstone Elsevier, 11th edition, 2010, 227-229
21. Kumar CR. Basic Pathology, Prism PVT. Limited Bangalore, 5th edition, 1992, 569-587.
22. DeFronzo RA, Bonadonna RC, Ferrannini E, Zimmet P. Pathogenesis of NIDDM,International Textbook of Diabetes Mellitus. 1997, 635-712
23. International Diabetes Federation (IDF) Diabetes Atlas – 10th ed. [cited 2021]. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
24. https://worldpopulationreview.com/country-rankings/diabetes-rates-by-country
25. HEARTS-D Module, https://www.who.int/publications/i/item/who-ucn-ncd-20.1
26. Chua SS, Kok LC, Md Yusof FA, et al. Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings. BMC Health Serv Res. 2012;12(1):1-10. doi:10.1186/1472-6963-12-388
27. Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization andcomparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabet Med. 2006;23(10):1100-1105.doi:10.1111/j.1464-5491.2006.01936.x
28. Pan CW, Sun HP, Zhou HJ, et al. Valuing health-related quality of life in type 2 diabetes patients in China. Med Decis Mak. 2016;36(2):234-241. doi:10.1177/0272989X15606903
29. 29.Karimi M, Brazier J. Health, Health-Related Quality of Life, and Quality of Life: Whatis the Difference? Pharmacoeconomics. 2016;34(7):645-649. doi:10.1007/s40273-016- 0389-9
30. 30.Alonso J, Ferrer M, Gandek B, et al. Health-related quality of life associated with chronic conditions in eight countries: Results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res. 2004;13(2):283-298. doi:10.1023/B:QURE.0000018472.46236.05
31. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self- rated health question: A meta-analysis. J Gen Intern Med. 2006;21(3):267- 275. doi:10.1111/j.1525- 1497.2005.00291.x
32. .Grandy S, Fox KM. EQ-5D visual analog scale and utility index values in individuals withdiabetes and at risk for diabetes: Findings from the Study to Help Improve Early evaluationand management of risk factors Leading to Diabetes (SHIELD). Health Qual Life Outcomes. 2008;6:18. doi:10.1186/1477-7525-6-18
33. Holmes J, McGill S, Kind P, Bottomley J, Gillam S, Murphy M. Health-related quality oflife in type 2 diabetes (T2ARDIS-2). Value Heal. 2000;3(SUPPL. 1):47-51. doi:10.1046/j.1524- 4733.2000.36028.x
34. Rajesh Nair, Paul Kanchan, Study performed in a private family practice clinic, Can Fam Physician, 2017, 63(6) e310-e315.
35. Bentley JP, Smith MC, Banahan 3rd BF, Frate DA, Parks BR. Quality of life assessment by community pharmacists: an exploratory study. Qual Life Res 1998; 7: 175–86.
36. Koopmanschap M. Diabetologia Coping with Type 11 Diabetes: The Patient’sPerspective.; 2002.
37. 37.Wexler DJ, Grant RW, Wittenberg E, et al. Correlates of health-related quality of life in type 2 diabetes. Diabetologia. 2006;49(7):1489-1497. doi:10.1007/s00125-006-0249-9
38. 38.Venkataraman K, Wee HL, Leow MKS, et al. Associations between complications andhealth- related quality of life in individuals with diabetes. Clin Endocrinol (Oxf). 2013;78(6):865-873. doi:10.1111/j.1365-2265.2012.04480.x
39. Jacobson A, Barofsky I, Cleary P, Rand L. Reliability and validity of a diabetes quality-of-life measure of the Diabetes Control and Complications Trial (DCCT). Diabetes Care. 1988;11(9):725-732. doi:10.2337/diacare.11.9.725
40. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: The ADDQoL. Qual Life Res. 1999;8(1-2):79-91. doi:10.1023/A:1026485130100
41. Power M, Kuyken W. World Health Organization Quality of Life Assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med. 1998;46(12):1569-1585. doi:10.1016/S0277-9536(98)00009-4
42. Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome - A review of quality of life measurement in adults with diabetes. Diabet Med. 2009;26(4):315-327. doi:10.1111/j.1464- 5491.2009.02682.x
43. Mateti U, Kunduru B, Akari S. Health-care cost of diabetes in South India: A cost of illnessstudy. J Res Pharm Pract. 2013;2(3):114. doi:10.4103/2279-042x.122382
44. Kim TH, Chun KH, Kim HJ, et al. Direct medical costs for patients with type 2 diabetes and related complications: A prospective cohort study based on the korean national diabetes program. J Korean Med Sci. 2012;27(8):876-882. doi:10.3346/jkms.2012.27.8.876
46. Blüher M, Kurz I, Dannenmaier S, Dworak M. Pill burden in patients with type 2 diabetesin Germany: Subanalysis from the prospective, noninterventional PROVIL study. Clin Diabetes. 2015;33(2):55-61. doi:10.2337/diaclin.33.2.55
47. Bernard DM, Banthin JS, Encinosa WE. Health care expenditure burdens among adults with diabetes in 2001. Med Care. 2006;44(3):210-215. doi:10.1097/01.mlr.0000199729.25503.60
48. Bansode B, Jungari DS. Economic burden of diabetic patients in India: A review. DiabetesMetab Syndr Clin Res Rev. 2019;13(4):2469-2472. doi:10.1016/j.dsx.2019.06.020
49. Suryavanshi MS, Yang Y. Incremental Burden on Quality of Life and Health Care Expenditures in Adults with Diabetes Complications: MEPS 2013–2015. J Gen Intern Med. 2019;34(6):812-814. doi:10.1007/s11606-019-04827-9
50. Rayappa PH, Raju K, Kapur A, Bjork S, Sylvest C, Kumar KMD. Economic cost of diabetes care: the Bangalore urban district diabetes study. Int J Diabet s Develpoping Ctries. 1999;19:87-97.
51. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff. 2010;29(2). doi:10.1377/hlthaff.2009.0155.
52. Bommer C, Heesemann E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423-430. doi:10.1016/S2213-8587(17)30097-9
53. Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol. 1997;43(4):343-348. https://doi.org/10.1046/j.1365-2125.1997.00574.x
54. McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 1: Introduction to the concepts of economic evaluation in health care. J Fam Plann Reprod Health Care. 2006;32(2):107- 112. https://doi.org/10.1783/147118906776276549
55. Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharmacy Practice 2021 Jan- Mar;19(1):2302.
56. 56. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimatesfor the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053. doi:10.2337/diacare.27.5.1047
57. 57. Mohan D, Raj D, Shanthirani CS, et al. Awareness and knowledge of diabetes in Chennai - The Chennai Urban Rural Epidemiology Study [CURES - 9]. J Assoc Physicians India. 2005;53(APR):283-287.
58. 58. Rao MB, Prašek M, Metelko Ž. Organization of diabetes health care in Indian ruralareas. Diabetol Croat. 2002;31(3):161-171. Accessed September 24, 2021.
https://web.archive.org/web/20180421100258id_/http://www.idb.hr/diabetologia/02no3- 3.pdf
59. Dall T, Mann SE, Zhang Y, et al. Economic costs of diabetes in the U.S. in 2007. DiabetesCare. 2008;31(3):596-615. doi:10.2337/dc08-9017
60. Chapman-Novakofski K. Epidemiology of Type 2 Diabetes. In: Nutraceuticals, GlycemicHealth and Type 2 Diabetes. Vol 125. ; 2009:11-27. doi:10.1002/9780813804149.ch2
61. Kapur A. Economic analysis of diabetes care. Indian J Med Res. 2007;125(3):473-482.Accessed September 25, 2021. http://www.ijmr.org.in
62. Singh J. Economic burden of diabetes high globally. PharmacoEconomics OutcomesNews. 2017;777(1):12-12. doi:10.1007/s40274-017-3951-6
63. Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: The associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8. doi:10.1186/1477-7525-8- 18
64. Guo X, Yao D, Liu J, Huang Y, Wang Y, Yao W. The current status of pharmaceutical care provision in tertiary hospitals: Results of a cross-sectional survey in China. BMC Health Serv Res. 2020;20(1):1-9. doi:10.1186/s12913-020-05371-7
65. Alsuwayt Saleh,; Almesned Mohammed; Alhajri Shahad; Alomari Naif; Alhadlaq Razan;Alotaibi Abdullah, Quality of life among type II diabetic patients attending the primary health centers of King Saud Medical City in Riyadh, Saudi Arabia, Journal of Family Medicine and Primary Care, 2021,10(8),3040-3046, doi: 10.4103/jfmpc.jfmpc_175_21
66. Jyoti Gupta, Dheeraj Kapoor, Vivek sood., Quality of Life and its Determinants in Patientswith Diabetes Mellitus from Two Health Institutions of Sub-Himalayan Region of India, Indian J Endocrinol Metab, 2021 :25(3):211-219, doi:10.4103/ijem.IJEM_246_21
67. Pattankar TP, Patil SS. Assessment of quality of life among known type 2 diabetics – A community based cross sectional study study in north Karnataka. Natl J Community Med.2019;10:429–34
68. Somappa HK, Venkatesh M, Prasad R. Quality of life assessment among type 2 diabetic patients in rural tertiary center. Int J Med Sci Public Health. 2014;34:415–7
69. Gutch M, Mohd Razi S, Kumar S, Gupta KK. Diabetes mellitus: Trends in northern India.Indian. J Endocrinol Metab. 2014;8:731–4
70. Rajashekaran D, Kulkarni V, Unnikrishnan B, Kumar N, Holla R, Thapar R. Self-care activities among patients with diabetes attending a tertiary care hospital in Manglore, Karnataka, India. Ann Med Health Sci Res. 2015;5:59–64
71. Kiadaliri AA, Najafi B, Mirmalek-Sani M. Quality of life in people with diabetes: A systematic review of studies in Iran. J Diabetes Metab Disord. 2013;12:54
72. Shanmugam srira,, Lini Elzibeth Chack, Rajeshwari Ramasamy, Ali Ghasemi, Thengungal, Kochupapy Ravi and Ali Mohammad Sabzghabaee, Impact of pharmaceuticalcare on quality of life in patients with type 2 diabetes mellitus, J Res Med Sci. 2011 Mar; 16(Suppl1): S412–S418.
73. Yingqi Xu ,Paul J. Gallagher D.,Cheryl W. Y. Tan .,Keith Y. K. Tsou , M.Med,David H.
Y. Tan , M.MeD,Henry Ramaya M.Med,, Impact of team based pharmaceutical care on the humanistic outcomes among patients with long standing diabetes: An interim analysis of a randomized, controlled, muilticenter study, Journal of the American college of clinical pharmacy,2021, https://doi.org/10.1002/jac5.1425
74. Muhammad Abubakar, Muhammad Atif, Impact of pharmacist led interventions on diabetes management at a community pharmacy in Pakistan:A randomized controlled trial,Inquiry2021, doi: 10.1177/00469580211036283
75. Kamal Sharma, A B. Chandorkar, Rajiv Kovil, S Venkataraman, KAV Subrahmanyam, Parthasarathi Mandal, Jasjeet Wasir, Mahesh Abhyankar, Ashish Prasad, Prashant S. Sarda, Expert Opinion About the Pharmacoeconomic Edge of Low- Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings, 2021, Cureus 13(11): e19194, doi:10.7759/cureus.19194
76. Sung-Hee Oh, Hyemin Ku,and Kang Seo Park, Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data, BMC Public Health. 2021; 21: 548.
77. James Shearer, Miral Kalyani, Anastasios Mangelis, Dileep de Silva, Padmal de Silva, Mahen Wijesuriya & Janaka Karalliedde, Cost-Effectiveness of Peer-Educator– Delivered Lifestyle Modification for Type 2 Diabetes Prevention in a Young Healthy Population in Sri Lanka: A Trial-Based Economic Evaluation and Economic Model, PharmacoEconomics,2021, 5,693–700.
78. Yesudian CA, Grepstad M, Visintin E, Ferrario A. The economic burden of diabetes in India: A review of the literature. Global Health. 2014;10(1). doi:10.1186/s12992-014- 0080-x
79. COVID-19 Guidance | ABCD (Diabetes Care) Ltd. Association of British Clinical Diabetologists. Published February 2020. Accessed September 26, 2021. https://abcd.care/coronavirus
80. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550. doi:10.1016/S2213- 8587(20)30152-2
81. Czernichow S, Bain SC, Capehorn M, et al. Costs of the COVID ‐19 pandemic associatedwith obesity in Europe: A health‐care cost model. Clin Obes. 2021;11(2). doi:10.1111/cob.12442
82. Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis ofinpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500-1515. doi:10.1007/s00125-020-05180-x
83. Ogunleye OO, Basu D, Mueller D, et al. Response to the Novel Corona Virus (COVID- 19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. FrontPharmacol. 2020;11. doi:10.3389/fphar.2020.01205
84. de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-populationstudy. Lancet. 2020;395(10238):1705-1714. doi:10.1016/S0140-6736(20)31030-8
85. Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):535-545. doi:10.1016/j.dsx.2020.04.044
86. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-218. doi:10.1016/j.kint.2020.05.006
87. Singh AK, Singh R. Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19? Diabetes Metab Syndr Clin Res Rev. 2020;14(5):725-727. doi:10.1016/j.dsx.2020.05.037
88. WHO. The Impact of the COVID-19 Pandemic on Noncommunicable Disease Resources and Services: Results of a Rapid Assessment.; 2020. Accessed September 26, 2021. https://www.who.int/publications/i/item/ncds-covid-rapid-assessment
89. Ebekozien OA, Noor N, Gallagher MP, Alonso GT. Type 1 diabetes and covid-19: Preliminary findings from a multicenter surveillance study in the U.S. Diabetes Care. 2020;43(8):e83-e85. doi:10.2337/dc20-1088
90. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-822. doi:10.1016/S2213-8587(20)30272-2
2. Davis TME, Clifford RM, Davis WA, Batty KT. The role of pharmaceutical care in diabetes management. Br J Diabetes Vasc Dis. 2005;5(6):352-356. doi:10.1177/14746514050050061001
3. Borges APDS, Guidoni CM, Ferreira LD, Freitas O De, Pereira LRL. The pharmaceuticalcare of patients with type 2 diabetes mellitus. Pharm World Sci. 2010;32(6):730-736. doi:10.1007/s11096- 010-9428-3
4. Helper CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. American Journal of Hospital Pharmacists.1990; 47:533–43.
5. American Society of Hospital Pharmacists. ASHP statement on pharmaceutical care. American Journal of Hospital Pharmacy.1993; 50:1720–30.
6. De Sá Borges AP, Guidoni CM, de Freitas O, Pereira LRL. Avaliação econômica de pacientes ambulatoriais portadores de diabetes melito tipo 2 assistidos por um serviço de atenção farmacêutica. Arq Bras Endocrinol Metabol. 2011;55(9):686-691. doi:10.1590/S0004-27302011000900003
7. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: Updating the cost-of-illness model. J Am Pharm Assoc (Washington, DC 1996). 2001;41(2):192-199. doi:10.1016/S1086-5802(16)31229- 3
8. Jameson JP, Baty PJ. Pharmacist Collaborative Management of poorly controlled diabetesmellitus: A randomized controlled trial. Am J Manag Care. 2010;16(4):250-255. AccessedSeptember 26, 2021. https://www.ajmc.com/view/ajmc_10apr_jameson_250to255
9. Krass I, Armour CL, Mitchell B, et al. The pharmacy diabetes care program: Assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24(6):677-683. doi:10.1111/j.1464-5491.2007.02143.x
10. Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of a community pharmacist intervention in diabetes care: A randomized controlled trial. J Clin Pharm Ther. 2011;36(5):602-613. doi:10.1111/j.1365-2710.2010.01218.x
11. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist- managed diabetes care services in a community health center. Am J Heal Pharm. 2006;63(21):2116-2122. doi:10.2146/ajhp060040
12. Royal S, Smeaton L, Avery AJ, Hurwitz B, Sheikh A. Interventions in primary care to reduce medication related adverse events and hospital admissions: Systematic review andmeta-analysis. Qual Saf Heal Care. 2006;15(1):23-31. doi:10.1136/qshc.2004.012153
13. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med. 2008;358(6):580-591. doi:10.1056/nejmoa0706245
14. Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J.1998;317(7160):703-713. doi:10.1136/bmj.317.7160.703
15. Kinge JM, Sælensminde K, Dieleman J, Vollset SE, Norheim OF. Economic losses and burden of disease by medical conditions in Norway. Health Policy (New York). 2017;121(6):691-698. doi:10.1016/j.healthpol.2017.03.020
16. Cohen LB, Taveira TH, Khatana SAM, Dooley AG, Pirraglia PA, Wu WC. Pharmacist- Led Shared Medical Appointments for Multiple Cardiovascular Risk Reduction in PatientsWith Type 2 Diabetes. Diabetes Educ. 2011;37(6):801-812.doi:10.1177/0145721711423980
17. Armour CL, Taylor SJ, Hourihan F, Smith C, Krass I. Implementation and evaluation of Australian pharmacists’ diabetes care services. J Am Pharm Assoc. 2004;44(4):455-466. doi:10.1331/1544345041475625
18. Hae MC, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive casemanagement of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: Arandomized controlled trial. Am J Manag Care. 2005;11(4):253-260. Accessed September 26, 2021. https://www.ajmc.com/view/apr05-2017p0253-0260
19. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care programin a free medical clinic. Am J Med Qual. 2000;15(4):137-142. doi:10.1177/106286060001500403
20. Kumar CR. Basic Pathology, Prism PVT. Limited Bangalore, 5th edition, 1992, 569-587.
2. Ross and Wilson. Anatomy and Pathophysiology in Health and Illness, Churchill Livingstone Elsevier, 11th edition, 2010, 227-229
21. Kumar CR. Basic Pathology, Prism PVT. Limited Bangalore, 5th edition, 1992, 569-587.
22. DeFronzo RA, Bonadonna RC, Ferrannini E, Zimmet P. Pathogenesis of NIDDM,International Textbook of Diabetes Mellitus. 1997, 635-712
23. International Diabetes Federation (IDF) Diabetes Atlas – 10th ed. [cited 2021]. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
24. https://worldpopulationreview.com/country-rankings/diabetes-rates-by-country
25. HEARTS-D Module, https://www.who.int/publications/i/item/who-ucn-ncd-20.1
26. Chua SS, Kok LC, Md Yusof FA, et al. Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings. BMC Health Serv Res. 2012;12(1):1-10. doi:10.1186/1472-6963-12-388
27. Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization andcomparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabet Med. 2006;23(10):1100-1105.doi:10.1111/j.1464-5491.2006.01936.x
28. Pan CW, Sun HP, Zhou HJ, et al. Valuing health-related quality of life in type 2 diabetes patients in China. Med Decis Mak. 2016;36(2):234-241. doi:10.1177/0272989X15606903
29. 29.Karimi M, Brazier J. Health, Health-Related Quality of Life, and Quality of Life: Whatis the Difference? Pharmacoeconomics. 2016;34(7):645-649. doi:10.1007/s40273-016- 0389-9
30. 30.Alonso J, Ferrer M, Gandek B, et al. Health-related quality of life associated with chronic conditions in eight countries: Results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res. 2004;13(2):283-298. doi:10.1023/B:QURE.0000018472.46236.05
31. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self- rated health question: A meta-analysis. J Gen Intern Med. 2006;21(3):267- 275. doi:10.1111/j.1525- 1497.2005.00291.x
32. .Grandy S, Fox KM. EQ-5D visual analog scale and utility index values in individuals withdiabetes and at risk for diabetes: Findings from the Study to Help Improve Early evaluationand management of risk factors Leading to Diabetes (SHIELD). Health Qual Life Outcomes. 2008;6:18. doi:10.1186/1477-7525-6-18
33. Holmes J, McGill S, Kind P, Bottomley J, Gillam S, Murphy M. Health-related quality oflife in type 2 diabetes (T2ARDIS-2). Value Heal. 2000;3(SUPPL. 1):47-51. doi:10.1046/j.1524- 4733.2000.36028.x
34. Rajesh Nair, Paul Kanchan, Study performed in a private family practice clinic, Can Fam Physician, 2017, 63(6) e310-e315.
35. Bentley JP, Smith MC, Banahan 3rd BF, Frate DA, Parks BR. Quality of life assessment by community pharmacists: an exploratory study. Qual Life Res 1998; 7: 175–86.
36. Koopmanschap M. Diabetologia Coping with Type 11 Diabetes: The Patient’sPerspective.; 2002.
37. 37.Wexler DJ, Grant RW, Wittenberg E, et al. Correlates of health-related quality of life in type 2 diabetes. Diabetologia. 2006;49(7):1489-1497. doi:10.1007/s00125-006-0249-9
38. 38.Venkataraman K, Wee HL, Leow MKS, et al. Associations between complications andhealth- related quality of life in individuals with diabetes. Clin Endocrinol (Oxf). 2013;78(6):865-873. doi:10.1111/j.1365-2265.2012.04480.x
39. Jacobson A, Barofsky I, Cleary P, Rand L. Reliability and validity of a diabetes quality-of-life measure of the Diabetes Control and Complications Trial (DCCT). Diabetes Care. 1988;11(9):725-732. doi:10.2337/diacare.11.9.725
40. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: The ADDQoL. Qual Life Res. 1999;8(1-2):79-91. doi:10.1023/A:1026485130100
41. Power M, Kuyken W. World Health Organization Quality of Life Assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med. 1998;46(12):1569-1585. doi:10.1016/S0277-9536(98)00009-4
42. Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome - A review of quality of life measurement in adults with diabetes. Diabet Med. 2009;26(4):315-327. doi:10.1111/j.1464- 5491.2009.02682.x
43. Mateti U, Kunduru B, Akari S. Health-care cost of diabetes in South India: A cost of illnessstudy. J Res Pharm Pract. 2013;2(3):114. doi:10.4103/2279-042x.122382
44. Kim TH, Chun KH, Kim HJ, et al. Direct medical costs for patients with type 2 diabetes and related complications: A prospective cohort study based on the korean national diabetes program. J Korean Med Sci. 2012;27(8):876-882. doi:10.3346/jkms.2012.27.8.876
46. Blüher M, Kurz I, Dannenmaier S, Dworak M. Pill burden in patients with type 2 diabetesin Germany: Subanalysis from the prospective, noninterventional PROVIL study. Clin Diabetes. 2015;33(2):55-61. doi:10.2337/diaclin.33.2.55
47. Bernard DM, Banthin JS, Encinosa WE. Health care expenditure burdens among adults with diabetes in 2001. Med Care. 2006;44(3):210-215. doi:10.1097/01.mlr.0000199729.25503.60
48. Bansode B, Jungari DS. Economic burden of diabetic patients in India: A review. DiabetesMetab Syndr Clin Res Rev. 2019;13(4):2469-2472. doi:10.1016/j.dsx.2019.06.020
49. Suryavanshi MS, Yang Y. Incremental Burden on Quality of Life and Health Care Expenditures in Adults with Diabetes Complications: MEPS 2013–2015. J Gen Intern Med. 2019;34(6):812-814. doi:10.1007/s11606-019-04827-9
50. Rayappa PH, Raju K, Kapur A, Bjork S, Sylvest C, Kumar KMD. Economic cost of diabetes care: the Bangalore urban district diabetes study. Int J Diabet s Develpoping Ctries. 1999;19:87-97.
51. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff. 2010;29(2). doi:10.1377/hlthaff.2009.0155.
52. Bommer C, Heesemann E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423-430. doi:10.1016/S2213-8587(17)30097-9
53. Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol. 1997;43(4):343-348. https://doi.org/10.1046/j.1365-2125.1997.00574.x
54. McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 1: Introduction to the concepts of economic evaluation in health care. J Fam Plann Reprod Health Care. 2006;32(2):107- 112. https://doi.org/10.1783/147118906776276549
55. Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharmacy Practice 2021 Jan- Mar;19(1):2302.
56. 56. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimatesfor the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053. doi:10.2337/diacare.27.5.1047
57. 57. Mohan D, Raj D, Shanthirani CS, et al. Awareness and knowledge of diabetes in Chennai - The Chennai Urban Rural Epidemiology Study [CURES - 9]. J Assoc Physicians India. 2005;53(APR):283-287.
58. 58. Rao MB, Prašek M, Metelko Ž. Organization of diabetes health care in Indian ruralareas. Diabetol Croat. 2002;31(3):161-171. Accessed September 24, 2021.
https://web.archive.org/web/20180421100258id_/http://www.idb.hr/diabetologia/02no3- 3.pdf
59. Dall T, Mann SE, Zhang Y, et al. Economic costs of diabetes in the U.S. in 2007. DiabetesCare. 2008;31(3):596-615. doi:10.2337/dc08-9017
60. Chapman-Novakofski K. Epidemiology of Type 2 Diabetes. In: Nutraceuticals, GlycemicHealth and Type 2 Diabetes. Vol 125. ; 2009:11-27. doi:10.1002/9780813804149.ch2
61. Kapur A. Economic analysis of diabetes care. Indian J Med Res. 2007;125(3):473-482.Accessed September 25, 2021. http://www.ijmr.org.in
62. Singh J. Economic burden of diabetes high globally. PharmacoEconomics OutcomesNews. 2017;777(1):12-12. doi:10.1007/s40274-017-3951-6
63. Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: The associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8. doi:10.1186/1477-7525-8- 18
64. Guo X, Yao D, Liu J, Huang Y, Wang Y, Yao W. The current status of pharmaceutical care provision in tertiary hospitals: Results of a cross-sectional survey in China. BMC Health Serv Res. 2020;20(1):1-9. doi:10.1186/s12913-020-05371-7
65. Alsuwayt Saleh,; Almesned Mohammed; Alhajri Shahad; Alomari Naif; Alhadlaq Razan;Alotaibi Abdullah, Quality of life among type II diabetic patients attending the primary health centers of King Saud Medical City in Riyadh, Saudi Arabia, Journal of Family Medicine and Primary Care, 2021,10(8),3040-3046, doi: 10.4103/jfmpc.jfmpc_175_21
66. Jyoti Gupta, Dheeraj Kapoor, Vivek sood., Quality of Life and its Determinants in Patientswith Diabetes Mellitus from Two Health Institutions of Sub-Himalayan Region of India, Indian J Endocrinol Metab, 2021 :25(3):211-219, doi:10.4103/ijem.IJEM_246_21
67. Pattankar TP, Patil SS. Assessment of quality of life among known type 2 diabetics – A community based cross sectional study study in north Karnataka. Natl J Community Med.2019;10:429–34
68. Somappa HK, Venkatesh M, Prasad R. Quality of life assessment among type 2 diabetic patients in rural tertiary center. Int J Med Sci Public Health. 2014;34:415–7
69. Gutch M, Mohd Razi S, Kumar S, Gupta KK. Diabetes mellitus: Trends in northern India.Indian. J Endocrinol Metab. 2014;8:731–4
70. Rajashekaran D, Kulkarni V, Unnikrishnan B, Kumar N, Holla R, Thapar R. Self-care activities among patients with diabetes attending a tertiary care hospital in Manglore, Karnataka, India. Ann Med Health Sci Res. 2015;5:59–64
71. Kiadaliri AA, Najafi B, Mirmalek-Sani M. Quality of life in people with diabetes: A systematic review of studies in Iran. J Diabetes Metab Disord. 2013;12:54
72. Shanmugam srira,, Lini Elzibeth Chack, Rajeshwari Ramasamy, Ali Ghasemi, Thengungal, Kochupapy Ravi and Ali Mohammad Sabzghabaee, Impact of pharmaceuticalcare on quality of life in patients with type 2 diabetes mellitus, J Res Med Sci. 2011 Mar; 16(Suppl1): S412–S418.
73. Yingqi Xu ,Paul J. Gallagher D.,Cheryl W. Y. Tan .,Keith Y. K. Tsou , M.Med,David H.
Y. Tan , M.MeD,Henry Ramaya M.Med,, Impact of team based pharmaceutical care on the humanistic outcomes among patients with long standing diabetes: An interim analysis of a randomized, controlled, muilticenter study, Journal of the American college of clinical pharmacy,2021, https://doi.org/10.1002/jac5.1425
74. Muhammad Abubakar, Muhammad Atif, Impact of pharmacist led interventions on diabetes management at a community pharmacy in Pakistan:A randomized controlled trial,Inquiry2021, doi: 10.1177/00469580211036283
75. Kamal Sharma, A B. Chandorkar, Rajiv Kovil, S Venkataraman, KAV Subrahmanyam, Parthasarathi Mandal, Jasjeet Wasir, Mahesh Abhyankar, Ashish Prasad, Prashant S. Sarda, Expert Opinion About the Pharmacoeconomic Edge of Low- Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings, 2021, Cureus 13(11): e19194, doi:10.7759/cureus.19194
76. Sung-Hee Oh, Hyemin Ku,and Kang Seo Park, Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data, BMC Public Health. 2021; 21: 548.
77. James Shearer, Miral Kalyani, Anastasios Mangelis, Dileep de Silva, Padmal de Silva, Mahen Wijesuriya & Janaka Karalliedde, Cost-Effectiveness of Peer-Educator– Delivered Lifestyle Modification for Type 2 Diabetes Prevention in a Young Healthy Population in Sri Lanka: A Trial-Based Economic Evaluation and Economic Model, PharmacoEconomics,2021, 5,693–700.
78. Yesudian CA, Grepstad M, Visintin E, Ferrario A. The economic burden of diabetes in India: A review of the literature. Global Health. 2014;10(1). doi:10.1186/s12992-014- 0080-x
79. COVID-19 Guidance | ABCD (Diabetes Care) Ltd. Association of British Clinical Diabetologists. Published February 2020. Accessed September 26, 2021. https://abcd.care/coronavirus
80. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550. doi:10.1016/S2213- 8587(20)30152-2
81. Czernichow S, Bain SC, Capehorn M, et al. Costs of the COVID ‐19 pandemic associatedwith obesity in Europe: A health‐care cost model. Clin Obes. 2021;11(2). doi:10.1111/cob.12442
82. Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis ofinpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500-1515. doi:10.1007/s00125-020-05180-x
83. Ogunleye OO, Basu D, Mueller D, et al. Response to the Novel Corona Virus (COVID- 19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. FrontPharmacol. 2020;11. doi:10.3389/fphar.2020.01205
84. de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-populationstudy. Lancet. 2020;395(10238):1705-1714. doi:10.1016/S0140-6736(20)31030-8
85. Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):535-545. doi:10.1016/j.dsx.2020.04.044
86. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-218. doi:10.1016/j.kint.2020.05.006
87. Singh AK, Singh R. Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19? Diabetes Metab Syndr Clin Res Rev. 2020;14(5):725-727. doi:10.1016/j.dsx.2020.05.037
88. WHO. The Impact of the COVID-19 Pandemic on Noncommunicable Disease Resources and Services: Results of a Rapid Assessment.; 2020. Accessed September 26, 2021. https://www.who.int/publications/i/item/ncds-covid-rapid-assessment
89. Ebekozien OA, Noor N, Gallagher MP, Alonso GT. Type 1 diabetes and covid-19: Preliminary findings from a multicenter surveillance study in the U.S. Diabetes Care. 2020;43(8):e83-e85. doi:10.2337/dc20-1088
90. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-822. doi:10.1016/S2213-8587(20)30272-2
Article Sidebar
Published
Nov 28, 2022
Article Details
How to Cite
Sadanandam Akari, & Sarumathy S. (2022). PHARMACEUTICAL CARE IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PHARMACO-ECONOMICAL BURDEN ON DIABETES PATIENT, COVID RECOVERED DIABETIC PATIENTS WITH CO-MORBID CONDITION. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 4457-4476. https://doi.org/10.53555/w4xxma59
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Sadanandam Akari
Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science & Technology, Kattankulathur, 603203, Chengalpattu, Tamil Nadu, India.
Sarumathy S
Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science & Technology, Kattankulathur, 603203, Chengalpattu, Tamil Nadu, India.
How to Cite
Sadanandam Akari, & Sarumathy S. (2022). PHARMACEUTICAL CARE IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PHARMACO-ECONOMICAL BURDEN ON DIABETES PATIENT, COVID RECOVERED DIABETIC PATIENTS WITH CO-MORBID CONDITION. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 4457-4476. https://doi.org/10.53555/w4xxma59